Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li><a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio Pharmaceuticals</a> tumbled as much as 39% on Monday after the <keyword id="45082" type="PERSON" weightage="60" keywordseo="biotech">biotech</keyword> firm announced a temporary hold on its mid-to-late-stage trial of a coronavirus vaccine.</li><li><a href="https://www.prnewswire.com/news-releases/inovio-reports-fda-partial-clinical-hold-for-planned-phase-2--3-trial-of-covid-19-vaccine-candidate-ino-4800-301138744.html">Inovio said</a> the trial is on "partial clinical hold" until it answers questions from the Food and Drug Administration, which it plans to do in October.</li><li>News of the study's halt triggered a trading pause of <keyword id="2901164" type="PERSON" weightage="60" keywordseo="Inovio">Inovio</keyword> shares before the opening bell.</li><li>Crucially, the hold isn't related to an adverse effect, and Inovio's phase-one trial is still moving forward.</li><li><a href="https://markets.businessinsider.com/stocks/ino-stock">Watch Inovio trade live here</a>.</li></ul>Shares of the biotech firm <a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio Pharmaceuticals</a> plummeted as much as 39% on Monday after the company announced a temporary pause to its mid-to-late-stage clinical trial of a coronavirus vaccine.<a href="https://www.prnewswire.com/news-releases/inovio-reports-fda-partial-clinical-hold-for-planned-phase-2--3-trial-of-covid-19-vaccine-candidate-ino-4800-301138744.html">Inovio said</a> the trial is on "partial clinical hold" until it adequately answers the Food and Drug Administration's questions about the trial and the delivery device to be used in it.Inovio said it planned to address the questions in October. Once it does, the FDA has 30 days to decide whether the clinical trial can move forward. Inovio's phase-one study is still proceeding.Read more: <a href="https://www.businessinsider.com/stock-market-crash-hedges-are-failing-more-downside-ahead-strategist-2020-9">'Expect more stock-market weakness': A Wall Street strategist lays out how investors' most-trusted defenses against crashes are failing them at a critical time</a>Premarket trading of <keyword id="9739816" type="UNKNOWN" weightage="60" keywordseo="inovio-stock">Inovio stock</keyword> was paused early Monday following the news. Shares tanked after the halt was lifted.Crucially, the trial hold isn't related to an adverse event. AstraZeneca made waves earlier this month after its phase-three trial of a vaccine candidate was paused because of a participant's adverse reaction. It remains paused in the US as <a href="https://www.cnn.com/2020/09/25/health/astrazeneca-covid-19-vaccine-trial-questions-fda/index.html">regulators investigate</a> whether participants' neurological illnesses are tied to the vaccine.Inovio stock closed at $16.94 per share on Friday, up nearly 400% year-to-date. The company has six "buy" ratings, one "hold" rating, and no "sell" ratings, with a median price target of $22.Now read more <keyword id="31671" type="CITY" weightage="100" keywordseo="markets">markets</keyword> coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/news/stocks/economic-outlook-wall-street-gdp-forecasts-slashed-stimulus-bill-unlikely-2020-9-1029624514">Wall Street economists are getting fed up with the government's inability to agree upon more stimulus</a><a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-value-outperform-tech-economic-expansion-correction-strategist-2020-9-1029624568">Stock investors should capitalize on the recent market correction by broadening portfolios beyond just tech, says one top Wall Street strategist</a><a href="https://www.businessinsider.com/stocks-to-buy-23-top-ideas-across-major-themes-ubs-2020-9">UBS: Buy these 23 stocks across major themes that are poised to outperform amid uncertainty and conflicting signals in the market</a><a href="https://markets.businessinsider.com/stocks/ino-stock"><div type="image" title="INO" height="1180" width="1456" msid="78366570" hostid="261"></div></a>

Inovio tanks 39% after pausing coronavirus vaccine trial, trading halted

<ul class="summary-list"><li>Inovio tumbled nearly 30% on Friday after the company said the government will stop funding a late-stage study of its COVID-19 <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> candidate. </li><li>Inovio said the decision stems from the 'rapid deployment of vaccines' and isn't a reflection on its INO-4800 candidate. </li><li>The biotech firm said it will work with its global partners on the Phase 3 vaccine trial. </li></ul><a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio Pharmaceuticals</a> shares were chopped down by nearly a third on Friday after the US government said it will discontinue funding for a late-phase trial of the company's COVID-19 vaccine candidate. The biotech company said it was informed that it will lose federal financial support for the phase three segment of its Innovate trial for INO-4800. The DNA vaccine candidate is aimed at preventing infection from SARS-CoV-2, the coronavirus behind the COVID-19 disease."The decision results from the changing environment of COVID-19 with the rapid deployment of vaccines," said Inovio in a statement. "This decision is not a reflection of the awardee or product, rather a fast-moving environment associated with the former Operation Warp Speed on decisions related to future products."Shares of the company dropped as much as 29% to $6.49 then slightly pared the loss to 25%. The moves put the stock down by roughly 22% since the start of 2021.The government will complete the funding for the phase 2 trial of INO-4800, the company said, which added that the phase 3 funding decision does not impact its other work with the US government.The US has been ramping up the nationwide rollout of COVID-19 vaccines made by <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> and <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a>. This week, President Joe Biden said his administration reached its goal of completing 200 million vaccine shots during his first 100 days in office.Inovio will continue working with other global partners on the late-stage study of INO-4800, including Advaccine Biopharmaceuticals, its partner in China.Inovio also said it will keep evaluating its pan-COVID variant vaccine, INO-4802, and assessing boosting capabilities for INO-4800."Inovio remains well-positioned to support both pandemic and endemic vaccine needs with INO-4800 and INO-4802," it said.

Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trial

<ul><li><keyword id="2901164" type="PERSON" weightage="60" keywordseo="Inovio">Inovio</keyword> has rallied 860% year-to-date as investors bid up the company's stock in hopes of the successful development of a vaccine for <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword>.</li><li>On Tuesday, Inovio fell as much as 17.8% after the company released early Phase I data on its INO-4800 <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword>.</li><li>The company said 94% of Phase I participants demonstrated an immune response to the vaccine candidate.</li><li>Inovio said its vaccine candidate was selected to participate in a non-human primate study as part of the US government's Operation Warp Speed.</li><li><a href="https://www.businessinsider.com/?utm_source=markets&amp;utm_medium=ingest?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener">Visit Business Insider's homepage for more stories</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio's</a> <a href="https://www.prnewswire.com/news-releases/inovio-announces-positive-interim-phase-1-data-for-ino-4800-vaccine-for-covid-19-301085537.html">Tuesday morning release</a> of early-stage data on its COVID-19 vaccine candidate sent shares lower by as much as 17.8%, giving the stock a breather after it rallied 860% year-to-date as of Monday's close.Investors have bid up the company on hopes that its vaccine candidate for COVID-19 proves successful in human trials.The interim Phase 1 data from Inovio showed that 94% of trial participants demonstrated overall immune response at week six after two doses of INO-4800, according to the company. Inovio said it plans to add older participants to its vaccine trial and to initiate a Phase 2/3 efficacy trial for INO-4800 later this summer, upon regulatory concurrence.Investors might be selling shares today due to a lack of information from the company.In a note published on Tuesday morning, Stifel said, "we believe this preliminary data is likely to raise more questions (vs. answers) on the competitive immunogenicity front and limits our ability to get more-constructive on INO shares based on this limited disclosure alone."Stifel downgraded shares of Inovio to Hold on June 26.Read more: <a href="https://www.businessinsider.com/stock-market-trades-strategies-recommendations-3q-earnings-season-3-experts-2020-6?r=US&amp;IR=T?utm_source=markets&amp;utm_medium=ingestm=ingest" target="_blank" rel="noopener noreferrer">We spoke with 3 financial experts, who said to make 4 these trades right now to get ahead of surprising gains when earnings season starts next month</a>Inovio also said its vaccine candidate was selected to participate in a non-human primate challenge study as part of the US government's Operation Warp Speed. <a href="https://markets.businessinsider.com/stocks/vxrt-stock">Vaxart</a> is another company working on a vaccine for COVID-19 that <a href="https://markets.businessinsider.com/news/stocks/vaxart-stock-price-covid-vaccine-government-warp-speed-program-coronavirus-2020-6-1029346082">was selected to participate in the same challenge study, which sent its stock soaring.</a>Operation Warp Speed is a private-public partnership by the federal government designed to speed up the development and production of a COVID-19 vaccine, therapeutics, and related diagnostics. Companies selected by the government to participate and receive funding include <a href="https://markets.businessinsider.com/stocks/mrk-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">Merck</a>, <a href="https://markets.businessinsider.com/stocks/mrna-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">Moderna</a>, <a href="https://markets.businessinsider.com/stocks/pfe-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">Pfizer</a>, <a href="https://markets.businessinsider.com/stocks/jnj-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">Johnson &amp; Johnson</a>, and <a href="https://markets.businessinsider.com/stocks/azn-stock?utm_source=markets&amp;utm_medium=ingestgest" target="_blank" rel="noopener">AstraZeneca</a>.<div type="image" title="inovio stock.JPG" height="714" width="1027" msid="76713684" hostid="261"></div>

Inovio's 860% year-to-date rally takes a breather after the release of Phase I data for company's COVID-19 vaccine candidate

<ul><li><a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio Pharmaceuticals</a> reported quarterly earnings results Monday that missed Wall Street's expectations. </li><li>Shares of the pharmaceutical company shed 12% in premarket trading Tuesday. </li><li>The company also said its <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> candidate will begin phase 2/3 clinical trials in the US in September, not over the summer as it had previously announced. </li><li><a href="https://markets.businessinsider.com/stocks/ino-stock">Watch Inovio Pharmaceuticals trade live on Markets Insider. </a></li><li><a href="https://www.businessinsider.com/">Read more on Business Insider. </a></li></ul>Shares of <a href="https://markets.businessinsider.com/stocks/ino-stock">Inovio Pharmaceuticals</a> shed as much as 12% in premarket trading Monday after the company reported quarterly results that missed Wall Street's expectations and said the next phase of trials for its <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword> candidate will begin later than previously announced. Here are the key numbers: <ul><li>Adjusted loss per share: 83 cents reported, versus 17 cents (expected) </li><li>Revenue: $267,000 reported, versus $2.6 million (expected) </li></ul>Read more: <a href="https://www.businessinsider.com/stock-picks-to-buy-cheap-small-mid-cap-companies-jpmorgan-2020-8">JPMorgan says buy these 19 'diamond in the rough' stocks that have plunged from yearly highs, but are spring-loaded for huge gains ahead</a>In the second quarter, Inovio's net loss was $128.7 million, up from $29.4 million in the same period last year. The increase was primarily driven by "the change in fair value of the derivative liability related to the embedded conversion feature in our August 2019 Convertible Bonds, which is revalued at each reporting period," the company said in a statement. Without that expense, the company's net loss would be 20 cents per share, instead of the 83 cents per share reported. Inovio also gave a timeline update on the status of its COVID-19 vaccine candidate, INO-4800. The company said it will begin its phase 2/3 clinical study in the US in September, and plans to expand manufacturing capacity to produce 100 million doses by 2021. Inovio had previously said that its COVID-19 vaccine candidate <a href="http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx">would enter the next phase of trials this summer. </a>The pharmaceutical company is up <a href="https://markets.businessinsider.com/stocks/ino-stock">475% this year through Monday's close. </a><a href="https://markets.businessinsider.com/stocks/ino-stock"><div type="image" title="Screen Shot 2020 08 11 at 8.28.35 AM" height="1198" width="1564" msid="77486083" hostid="261"></div></a>

Inovio Pharmaceuticals sheds 12% after earnings miss, update on its COVID-19 vaccine

<div class="KonaFilter image-container display-table"><div><div class="image on-image">IntelDiane Bryant</div></div></div><ul class="summary-list"><li>One of <a href="https://www.businessinsider.com/category/intel">Intel's</a> most storied former executives, Diane Bryant, is quietly making a come-back in the tech industry.</li><li>On Monday, Los Angeles-based video cloud company OwnZones announced that Bryant had joined its advisory board.</li><li>This follows news earlier this year that she had joined Broadcom's board. </li></ul>One of Intel's most storied former executives, Diane Bryant, is quietly dipping her toes back in the tech industry. On Monday, Los Angeles-based video cloud company <a href="https://www.prweb.com/releases/ownzones_entertainment_technologies_appoints_former_google_cloud_coo_diane_m_bryant_to_its_advisory_board/prweb16397750.htm">OwnZones announced that Bryant</a> had joined its advisory board.OwnZones is an interesting company and an interesting choice for Bryant to join. OwnZones offers makers of TV, movie, and video content a way to easily convert video ino formats that can be streamed over the internet. Its technology <a href="https://ownzones.com/case-study/magnolia-pictures/">is used,</a> for instance, when a movie distributor like Mark Cuban's Magnolia Pictures wants to release its films on Netflix, YouTube and Tubi. Interestingly, OwnZones was founded by a former Microsoftie<a href="https://www.crunchbase.com/person/dan-goman#section-overview">, Dan Goman</a>, who, back in the day, worked in Microsoft's Windows Media division. Bryant was at Intel during those days, the heyday of the so-called Wintel world.Bryant left Intel in 2017, after a 32-year-career there, and resurfaced months later in December, 2017, as the COO of <a href="https://www.businessinsider.com/category/google">Google's</a> cloud, under Google's then cloud chief Diane Greene. But it wasn't a fit and about 7 months later she left Google, too. (Months later, Greene also left Google.)Her name came up again as a potential prospect when Intel was searching for its new CEO after Brian Krzanich resigned when he admitted to having an affair with a subordinate. Krzanich bounced himself into a new CEO job pretty quickly, leading automotive dealership software company, CDK Global.At Intel, Bryant was the face of the Data Center Group, which booked $17 billion in revenue in 2016 - a huge business and one of Intel's high spots as its traditional PC market shrank. She was a frequent public speaker for Intel, known as one of the most powerful women in tech. And she has an inspiring past: homeless at age 18 after graduating high school, she studied math at a then-free community college and got into engineering after someone told her it was a good-paying field. She landed at Intel and worked her way up the ladder from there.In May, she gave $500,000 to that community college that changed her life. American River College, for its new STEM center, <a href="https://fox40.com/2019/05/22/former-google-executive-donates-500000-to-arcs-new-stem-center/">reports Fox40.</a>But Bryant has been mostly under the radar since she left Google.Right now, she's doing board-of-directors gigs. She's on the board of United Technologies Corp (UTC), where she's served since early 2017. And in January, she joined Broadcom's board, one of Intel's fiercest competitors. She's also on the UC Davis Chancellor's Board of Advisors and UC Davis College of Engineering Board of Advisors.The role at OwnZones is on the advisory board, not the board of directors. Still, we've been expecting to hear news of her landing at a startup, or possibly her own CEO role, like her former colleague <a href="https://www.businessinsider.com/former-intel-exec-renee-james-has-launched-a-new-chip-company-2018-2">Renee James has done with her chip company, Ampere.</a>That hasn't happened yet, but as Bryant adds board and advisory roles to her docket, she's inching her way back into the tech scene again.Get the latest Google stock price<a href="http://markets.businessinsider.com/stock/GOOG-Quote"> here.</a> <div class="margin-top"> <h3>NOW WATCH: <a href="https://www.businessinsider.com/stewart-butterfield-advice-for-millenials-2015-7">Stewart Butterfield, co-founder of Slack and Flickr, says 2 beliefs have brought him the greatest success in life</a></h3> <div> </div> </div>

Former Intel and Google cloud exec Diane Bryant is easing back into the saddle with new board roles

<div class="KonaFilter image-container display-table float_right"><div><div class="image"><a href="http://www.amazon.com/Ioan-Grillo/e/B0051P7GK6/ref=dp_byline_cont_book_1" target="_blank"></div></div></div>As we step inside, a cocktail of mystic toxic smells greets us. To the left, towers of cling-wrapped marijuana loom above over our heads. To the right are huge sacks of cut-up ganja plants and enough seeds to give birth to a forest of psychedelic weed. Walking forward, we stumble into a pile of giant, blue metal saucepans of the type Mexicans use in the restaurant to cook up broths such as posole and consomme.General Solorzano lifts up a lid of one and flashes a knowing grin: "This is crystal." He smiles. The white sludge of raw methamphetamine fills the pan like a foul stew of ice and sour milk. In a corner, we catch sight of a much older Sinaloan product, black-tar heroin, which looks like jet-black Play-Doh, oozing out of yellow cans.<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div>An inventory neatly lists the name of each type of drug next to a quantity in kilos; they currently total more than seven tons.Periodically, a bureaucrat in an office somewhere will sign the order for a certain batch of heroin or marijuana or crystal meth to be carted away and burned on a bonfire.But stocks are quickly replenished by a steady supply of new produce garnered in weekly raids on safe houses scattered all around Culiacan and in nearby villages and ranches.<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div>On the afternoon of our visit, one such load conveniently arrives for us to photograph. A truck rolls up and young soldiers move with military orderliness to unload hundreds of brown packages into the warehouse. General Solorzano grabs one, reaches into his black vest for a box cutter, and carefully slices a triangle in the packaging to reveal white powder crammed into a brick shape. "Cocaina!" he says triumphantly. <div class="KonaFilter image-container display-table float_right"><div><div class="image"></div></div></div>A lab technician quickly proves him right. The white-coated specialist conducts the test using a portable kit, which looks like a car toolbox. He selects a vial of pink solution, mixes it with a small sample of the captured blow, and it instantly turns blue - indicating a positive match.General Solorzano, a foot lower than me but with shoulders twice as broad, turns round and stares me in the face."Taste it," he says, unsmiling. "Go on."I look round at the other officers, agents, and technicians to see if he is joking. They all have sturdy straight faces. So I dab my little finger onto the cocaine brick and stick it into my mouth.Cocaine has an unforgettable bittersweet flavor, neither tasty nor disgusting, like a prescription medicine you cautiously swallow and are then relived that it isn't so bad. "You will feel that your tongue falls asleep," General Solorzano says, a grin now spreading across his face. "This is pure, uncut cocaine." My tongue certainly does feel numb. And I also feel a little giddy. But then again, maybe that is from walking in the hot sun. Or maybe it is from earlier in the day when we watched soldiers cut up a whole field of captured marijuana and set fire to it, sparking a golden green blaze that unleashed clouds of ganja smoke wafting off into the horizon in these arid, jaggy mountains.Republished with permission from <a href="http://www.amazon.com/El-Narco-Mexicos-Criminal-Insurgency/dp/1608194019" target="_blank">El Narco: Inside Mexico's Criminal Insurgency</a> by Ioan Grillo. Copyright © 2011 by Ioan Grillo. Reprinted by arrangement with Bloomsbury Publishing. All rights reserved. <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/smartphone-impact-brain-body-sleep-2015-2">This is what happens to your brain and body when you check your phone before bed</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="BvMjVqcjoHdZBG6tTpXy8UkhB5_46U_c" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

You Searched For "ino stock" and got 6 results

Inovio tanks 39% after pausing coronavirus vaccine trial, trading halted

Ben Winck

Inovio sinks 26% after US government decides to discontinue funding for next phase of COVID-19 vaccine trial

Carla Mozée

Inovio's 860% year-to-date rally takes a breather after the release of Phase I data for company's COVID-19 vaccine candidate

Matthew Fox

Inovio Pharmaceuticals sheds 12% after earnings miss, update on its COVID-19 vaccine

Carmen Reinicke

Former Intel and Google cloud exec Diane Bryant is easing back into the saddle with new board roles

Julie Bort

What it's like in the drug evidence warehouse of a Mexican military base

Ioan Grillo, "El Narco"

Popular Keywords

Buying Guides